ATE404191T1 - Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist - Google Patents
Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonistInfo
- Publication number
- ATE404191T1 ATE404191T1 AT03785782T AT03785782T ATE404191T1 AT E404191 T1 ATE404191 T1 AT E404191T1 AT 03785782 T AT03785782 T AT 03785782T AT 03785782 T AT03785782 T AT 03785782T AT E404191 T1 ATE404191 T1 AT E404191T1
- Authority
- AT
- Austria
- Prior art keywords
- dpp
- inhibitor
- conditions
- ppar
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43219202P | 2002-12-10 | 2002-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE404191T1 true ATE404191T1 (de) | 2008-08-15 |
Family
ID=32507865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03785782T ATE404191T1 (de) | 2002-12-10 | 2003-12-09 | Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060111428A1 (de) |
| EP (1) | EP1572196B1 (de) |
| JP (1) | JP2006512334A (de) |
| CN (1) | CN100348189C (de) |
| AT (1) | ATE404191T1 (de) |
| AU (1) | AU2003294824A1 (de) |
| BR (1) | BR0317028A (de) |
| CA (1) | CA2505771A1 (de) |
| DE (1) | DE60322944D1 (de) |
| ES (1) | ES2311117T3 (de) |
| PT (1) | PT1572196E (de) |
| WO (1) | WO2004052362A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1723196A (zh) | 2001-06-27 | 2006-01-18 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| JP2008505176A (ja) | 2004-06-30 | 2008-02-21 | コンビナトアールエックス インコーポレーティッド | 代謝障害を治療するための方法および試薬 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| KR20080000665A (ko) | 2005-04-22 | 2008-01-02 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 디펩티딜 펩티다아제-ⅳ 억제제 |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1785133A1 (de) * | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2108960A1 (de) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR101054911B1 (ko) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
| CA2795513A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| EP3323818A1 (de) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CN103619334A (zh) * | 2011-01-19 | 2014-03-05 | 朱红文 | 噻唑烷衍生物和其治疗用途 |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EP3110449B1 (de) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medizinische verwendung eines dpp-4-inhibitors |
| CN104529857B (zh) * | 2015-01-13 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 卤代金刚烷酰胺类衍生物、其制备方法和用途 |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| EP1743655B1 (de) * | 2000-01-21 | 2014-06-25 | Novartis AG | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| JP2003523336A (ja) * | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| WO2002044130A1 (fr) * | 2000-11-29 | 2002-06-06 | Kyorin Pharmaceutical Co., Ltd. | Dérivés d'acide carboxylique substitués |
| CA2437118A1 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| EP1385508B1 (de) * | 2001-03-27 | 2008-05-21 | Merck & Co., Inc. | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| ES2257555T3 (es) * | 2001-06-20 | 2006-08-01 | MERCK & CO., INC. | Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes. |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
-
2003
- 2003-12-09 AT AT03785782T patent/ATE404191T1/de active
- 2003-12-09 CA CA002505771A patent/CA2505771A1/en not_active Abandoned
- 2003-12-09 BR BR0317028-4A patent/BR0317028A/pt unknown
- 2003-12-09 AU AU2003294824A patent/AU2003294824A1/en not_active Abandoned
- 2003-12-09 CN CNB2003801052605A patent/CN100348189C/zh not_active Expired - Fee Related
- 2003-12-09 EP EP03785782A patent/EP1572196B1/de not_active Expired - Lifetime
- 2003-12-09 ES ES03785782T patent/ES2311117T3/es not_active Expired - Lifetime
- 2003-12-09 PT PT03785782T patent/PT1572196E/pt unknown
- 2003-12-09 DE DE60322944T patent/DE60322944D1/de not_active Expired - Lifetime
- 2003-12-09 WO PCT/EP2003/013963 patent/WO2004052362A1/en not_active Ceased
- 2003-12-09 JP JP2004558050A patent/JP2006512334A/ja active Pending
- 2003-12-09 US US10/537,870 patent/US20060111428A1/en not_active Abandoned
-
2008
- 2008-08-12 US US12/190,149 patent/US20080300293A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004052362A1 (en) | 2004-06-24 |
| CN100348189C (zh) | 2007-11-14 |
| US20080300293A1 (en) | 2008-12-04 |
| EP1572196A1 (de) | 2005-09-14 |
| JP2006512334A (ja) | 2006-04-13 |
| US20060111428A1 (en) | 2006-05-25 |
| CN1720042A (zh) | 2006-01-11 |
| HK1085377A1 (en) | 2006-08-25 |
| CA2505771A1 (en) | 2004-06-24 |
| BR0317028A (pt) | 2005-10-25 |
| DE60322944D1 (de) | 2008-09-25 |
| PT1572196E (pt) | 2008-11-20 |
| EP1572196B1 (de) | 2008-08-13 |
| AU2003294824A1 (en) | 2004-06-30 |
| ES2311117T3 (es) | 2009-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60322944D1 (de) | Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist | |
| DE60301491D1 (en) | Acc-hemmer | |
| BRPI0401699A (pt) | Processo para a destilação de uma mistura de diisocianatodifenilmetanos isÈmeros | |
| AU2003293892A1 (en) | Method for the purification of isocyanates | |
| EP1283058A4 (de) | Agentia zur hemmung oder verbesserung von insulinresistenz und/oder obesität | |
| WO2004056315A8 (en) | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | |
| EP2277512A3 (de) | Pharmazeutische Zusammensetzungen und Dosierungsformen von Thalidomid | |
| BRPI0518409A2 (pt) | combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina | |
| WO2004103294A3 (en) | Methods and compositions for the prevention and treatment of sepsis | |
| WO2007024949A3 (en) | Alpha2c adrenoreceptor agonists | |
| AR019671A1 (es) | Uso de una cantidad terapeuticamente efectiva de (+) norcisaprida o una sal farmacologicamente aceptable de la misma sustancialmente libre de su (-)estereoisomero, para la preparacion de un medicamento | |
| CL2007003176A1 (es) | Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis. | |
| WO2005118511A3 (en) | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | |
| WO2002064136A3 (en) | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | |
| DE60323765D1 (de) | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
| WO2004096067A3 (en) | Bone fixture apparatus | |
| NO20060360L (no) | Nye 8-azabisyklo [3.2.1] oktanderivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer | |
| MY130792A (en) | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
| NZ591136A (en) | A composition for treating aids and associated conditions comprising plant extracts | |
| RU2004104457A (ru) | Композиции, обладающие ингибирующим продуцирование tnf действием, и ингибиторы продуцирования tnf | |
| EP2002721A3 (de) | Teesamen-Rückstände und natürliche Teesaponin-Produkte | |
| Bollenbach et al. | Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation | |
| EP1569634B8 (de) | Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitas | |
| AR020327A1 (es) | Uso de una cantidad terapeuticamente efectiva de (-)norcisaprida, o una sal farmacologicamente aceptable de la misma, sustancialmente libre de su (+)estereoisomero, para la preparacion de medicamentos. | |
| AU2003223070A1 (en) | Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1572196 Country of ref document: EP |